;

House Publications

The Debates are the report—transcribed, edited, and corrected—of what is said in the House. The Journals are the official record of the decisions and other transactions of the House. The Order Paper and Notice Paper contains the listing of all items that may be brought forward on a particular sitting day, and notices for upcoming items.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Bilingual view PDF

Notice Paper

No. 335

Wednesday, June 19, 2024

2:00 p.m.

Introduction of Government Bills

Introduction of Private Members' Bills

June 18, 2024 — — Bill entitled “An Act to establish a national framework to improve food price transparency”.

Notices of Motions (Routine Proceedings)

June 18, 2024 — — That the intervention made by the member for Saskatoon West in the Debates of June 4, 2024, be amended to ensure the correctness of the records of the House, pursuant to Standing Order 67(1)(p), by replacing the words “One of the interesting things in that particular incident was that the perpetrator, Myles Sanderson, had a history of violent offences and had been recently released on parole, despite the prediction by the parole board that he was likely to reoffend regardless of his racial background.”, with the words “One of the interesting things in that particular incident was that the perpetrator, Myles Sanderson, had a history of violent offences and had been recently released on parole, despite the prediction by the parole board that he was likely to reoffend because of his racial background.”.

Questions

Q-2905² — June 18, 2024 — — With regard to budget 2024 and the government’s subsequent amendments to the Canada Student Financial Assistance Act and the Canada Student Loans Act: (a) what criteria did the government use to develop the list of health care professionals and social services professionals included in the amendments; (b) which health care professionals and social services professionals were included in the assessments in (a); (c) for each health care professional and social services professional included in the assessments but not included in the amendments, what is the rationale to exclude the professionals from the final list; (d) what is the total expected cost of the loan forgiveness measures announced in budget 2024, broken down by profession; and (e) what was the estimated cost of including occupational therapists in the loan forgiveness program?

Q-2906² — June 18, 2024 — — With regard to the National Trade Corridors Fund (NTCF): (a) under the “National Call to Address Capacity Constraints” first call for proposals in July 2017, how many projects were approved for British Columbia; (b) under the “Continuous call for Trade Diversification” launched on January 15, 2019, how many projects were approved for British Columbia; (c) under the “lncreasing the Fluidity of Canada's Supply Chains” launched on December 9, 2021, how many projects were approved for British Columbia; (d) under the “Relieving Supply Chain Congestion at Canadian Ports” launched on January 31, 2022, how many projects were approved for British Columbia; (e) under the “Advancing Supply Chain Digitalization” launched on February 13, 2023, how many projects were approved for British Columbia; (f) what is the current status of every NTCF funded project in British Columbia; and (g) how much program spending has been done each year since 2017-18?

Q-2907² — June 18, 2024 — — With regard to budget 2024 which stated that the changes to capital gains taxes would increase federal revenues by $19.4 billion over five years starting in 2024-25: (a) how did the government arrive at this figure; and (b) what data sources were used?

Q-2908² — June 18, 2024 — — With regard to changes in capital gains taxes as announced in budget 2024: after removing capital gains income from the calculation of total personal income, what is the share of capital gains tax revenue collected from those earning (i) equal or less than $50,000, (ii) between $50,001 and $100,000, (iii) between $100,001 and $150,000, (iv) over $150,000?

Q-2909² — June 18, 2024 — — With regard to the Assessment Framework and Guidelines that deliver on Canada’s G7 and G20 commitments to phase out or rationalize inefficient fossil fuel subsidies: (a) how many tax and non-tax measures have been assessed and met the criteria to be considered an efficient fossil fuel subsidy; and (b) for each tax and non-tax measure identified in (a), which of the six criteria identified in the framework were met?

Q-2910² — June 18, 2024 — — With regard to the pilot system for rapid heat wave attribution: (a) which heat waves have been assessed to calculate how much human-caused global warming changed the risks of such an event occurring, including during the development of the system; (b) what steps are being taken and what is the expected timeline to expand the pilot to include extreme cold weather events and extreme precipitation; and (c) are there plans to expand the pilot to include wildfires, drought, and floods?

Q-2911² — June 18, 2024 — — With regard to the 2 Billion Trees Commitment, broken down by province or territory since its inception: (a) what is the total amount of funding allocated under each of the (i) cost-sharing agreements with provinces and territories, (ii) Privates Lands stream, (iii) Urban Lands stream, (iv) Federal Lands stream, (v) distinctions based Indigenous stream; (b) what is the total amount of funding delivered under each of the (i) cost-sharing agreements with provinces and territories, (ii) Privates Lands stream, (iii) Urban Lands stream, (iv) Federal Lands stream, (v) distinctions based Indigenous stream; and (c) what is the total amount of funding on hold or undelivered under each of the (i) cost-sharing agreements with provinces and territories, (ii) Privates Lands stream, (iii) Urban Lands stream, (iv) Federal Lands stream, (v) distinctions based Indigenous stream?

Q-2912² — June 18, 2024 — — With regard to species listed under the Species at Risk Act since October 2015, broken down by status (i.e. extirpated, endangered, threatened and special concern): (a) how many recovery strategies or management plans were (i) produced within the timelines set out in the act, (ii) overdue; (b) how many action plans required to support the implementation of recovery strategies were (i) produced within the timelines set out in the act, (ii) overdue; (c) how many species do not yet have recovery strategies or management plans; and (d) how many recovery strategies do not yet have action plans?

Q-2913² — June 18, 2024 — — With regard to contracts between any government department, agency, Crown corporation, or other government entity and Speakers Spotlight, since November 4, 2015: what are the details of each contract, including the (i) date of event associated with the contract, (ii) amount, (iii) name of the speaker, (iv) event description and purpose of the speech?

Q-2914² — June 18, 2024 — — With regard to the increase to capital gains taxes announced in budget 2024: prior to the release of budget 2024, did the government consult anyone on these tax increases, and, if so, what are the details, including (i) who was consulted, (ii) how they were consulted, (iii) when they were consulted?

Q-2915² — June 18, 2024 — — With regard to the terms of the Pacific Salmon Commercial Licence Retirement Program (LRP) under the Pacific Salmon Strategy Initiative (PSSI), broken down by each harvest area: (a) how many individual commercial salmon licenses have been retired each year broken down by gear type; (b) what were the average prices paid; and (c) what were the highest and lowest prices?

Q-2916² — June 18, 2024 — — With regard to Health Canada's (HC) decision to approve the COVID-19 modRNA vaccines and the Prime Minister's subsequent support for the vaccine mandates in the federal public sector and vaccine passports for travel purposes during the COVID-19 pandemic: (a) what is the immunological mechanism of action of the COVID-19 mRNA vaccines that enables them to stop the spread of SARS-CoV2; (b) what data supports this mechanism of action; (c) who or what agency provided the data and verified the data; (d) when was this data provided to (i) HC, (ii) the Office of the Prime Minister; (e) what data did Pfizer and Moderna produce to HC that demonstrated (i) the period of time the spike protein is produced in the body, (ii) where in the body the spike protein is produced; and (f) in relation to (e), what was the period of time Pfizer and Moderna tracked the spike protein in their clinical studies?

Q-2917² — June 18, 2024 — — With regard to Health Canada's (HC) establishing the safety of the Pfizer/BioNTech COVID-19 vaccine in 12-15 year olds: (a) what serious adverse events (SAEs) did the pharmaceutical company disclose to Canada's health agencies for this age group pre-authorization; (b) since approving the product in this age group, has the Public Health Agency of Canada (PHAC), the National Advisory Committee on lmmunization (NACI) or HC become aware of additional adverse events (AEs) or SAEs that the pharmaceutical company had not disclosed during the initial authorization process; (c) if the answer to (b) is affirmative, (i) what AEs and SAEs has the PHAC, the NACI and HC become aware of, (ii) when were they discovered, (iii) what are the means by which Canada's health agencies were provided this information; (d) prior to authorizing this product in this age group, was the PHAC, HC or the NACI given information about (i) the SAEs of a 12-year-old trial participant named Maddie de Geray who was diagnosed with chronic inflammatory demyelinating polyneuropathy which rendered her reliant on a wheelchair and feeding tube, (ii) any other specific SAE cases in this cohort following the Pfizer inoculation; (e) if the answer to (d) is affirmative, what was the date and means by which the PHAC, the NACI or HC became aware of these cases; (f) if the answer to (d) is negative, has Ms. De Geray's diagnoses been added to HC's list of SAEs on the HC website in this age group; (g) has the PHAC, HC or the NACI been aware that the adverse events experienced by trial participant Maddie de Geray were not properly disclosed within their trial studies as described in the scientific publication of said trial (i.e. NEJM - Frenck et al. 2021); (h) did the PHAC, HC or the NACI take any action after discovering the lack of proper disclosure of Maddie de Geray's SAEs by Pfizer; (i) what was the age stratified risk-benefit analysis for 12-15 year olds in relation to the Pfizer/BioNTech COVID-19 vaccine at the time of authorization, on May 5, 2021; (j) what was the data and calculations for quantifying the risks and benefits that Canadian health agencies used to authorize or approve the product in this age group; (k) what data indicated that the benefits of the vaccine outweighed the risks at the time of authorization; (l) since the roll-out of the Pfizer/BioNTech COVID-19 vaccine in this age group, (i) what are the top ten SAEs identified in this cohort, (ii) how have these SAEs been communicated to the medical community and the public at large; (m) what type and frequency of SAEs in 12-15-year-old would invoke an unfavourable benefits-risk ratio for healthy children and for children with underlying medical conditions; and (n) is HC, the PHAC or the NACI aware of any other jurisdictions worldwide that no longer recommends the mRNA COVID-19 vaccines in children at (i) six months of age, (ii) between six months and two years (iii) between two to five years, (iv) between five to 12 years, (v) between 12-15 year, (vi) between 15-18 years?

Q-2918² — June 18, 2024 — — With regard to Health Canada's (HC) review of the COVID-19 modRNA vaccine products: (a) did HC consider the specific nature of the nanotechnology of the lipid particles used for the modRNA vaccine delivery; (b) if the answer to (a) is affirmative, what was their assessment; (c) why was the fact that modRNA vaccines contain nanotechnology omitted from the product monograph-label; (d) did HC assess the toxicity of pegylated nanoparticles, specifically the risk for complement activated related pseudo allergy (CARPA) with the lipid nanoparticles used in the mRNA vaccines; (e) if the answer to (d) is affirmative, why was this not included in the product labelling; (f) if the answer to (d) is negative, why wasn't this assessed; (g) did HC assess the risk of toxicity due to the nanoformat of these vaccines; (h) if the answer to (g) is affirmative, what was the assessment result; (i) if the answer to (g) is negative, why not; (j) did HC assess the lipid nanoparticles as a novel excipient; (k) if the answer to (j) is affirmative, what was the assessment; (l) if the answer to (j) is negative, why not; (m) with respect to nanotechnology products and their unique properties and behaviors particularly in their application to the modRNA vaccines, did HC examine (i) the safety, (ii) the effectiveness, (iii) the risk to the environment, (iv) its specific regulatory status; (n) if the answers to (m)(i) to (m)(iv) is affirmative, what were the assessment results; (o) if the answers to (m)(i) through (m)(iv) is negative, why not; (p) how do established safe levels of DNA apply, (i) when using pegylated LNPs as a delivery system, (ii) when a product that contains pegylated LNPs requires repeated dosing; and (q) what assessment was performed to assess the risk of residual DNA when using pegylated LNPs as a delivery system in a vaccine which requires repeated dosing?

Q-2919² — June 18, 2024 — — With regard to the project “Board of Education of School District No. 62 (Sooke)” under Health Canada's Substance Use and Addictions Program, broken down by participating elementary, middle and secondary schools: (a) what are the names of the schools; (b) what is the cost of the curriculum, broken down by subject, which is being taught to the students; (c) what are the total number of materials that are being disseminated to the students, in total, and broken down by the names and titles of those materials; (d) broken down by schedule I, II, and III drugs and substances as defined by the Controlled Drugs and Substances Act, how much of the total funding is being allocated to each specific “primary focus” as defined by the program, broken down by each specific drug and substance; (e) how many staff or volunteers are being funded; and (f) is it a mandatory requirement for all staff or volunteers to undergo a criminal background check, and (i) have staff or volunteers been subjected to criminal background checks, (ii) have any criminal background checks for staff or volunteers turned up criminal convictions that are indictable or summary convictions, (iii) was any hired as staff or a volunteer with an indictable or summary conviction?

Q-2920² — June 18, 2024 — — With regard to a Statistics Canada report titled “Police-reported crime statistics in Canada, 2022”, The Daily — Police-reported crime statistics in Canada, 2022, and the report that there has been a 43% increase in the rates of level 1, 2, and 3 sexual assaults between 2015 and 2022: (a) does Public Safety Canada acknowledge that level 1, 2, and 3 sexual assaults have increased 43% in that time period, and, if not, why not; (b) when did Public Safety Canada learn of the 43% increase in the rates of level 1, 2, and 3 sexual assaults; (c) how long was the delay between Public Safety Canada learning of the 43% increase and the establishment of mitigation measures to reduce the number of level 1, 2, and 3 sexual assaults, broken down by the dates the measures were undertaken by Public Safety Canada and its public safety partner agencies; (d) has Public Safety Canada and its public safety partner agencies taken measures to mitigate this increase of level 1, 2, and 3 sexual assaults broken down by specific measures, including the funds allocated and spent by each specific mitigation measures?

Q-2921² — June 18, 2024 — — With regard to the Canada Border Services Agency's (CBSA) Request for Assistance Program (RFA), which has historically been an effective tool for Intellectual Property (IP) rights owners to prevent counterfeit goods from crossing the Canadian border and entering the commerce stream, and having cut the RFA program significantly: (a) does the government have plans to (i) reassess the cuts to training and processes that limit CBSA officers from efficiently searching, identifying and detaining the counterfeit products, (ii) reinvest in the RFA program in the next years, and, if so, when, (iii) work and discuss the impacts that these cuts have had on Canadians, businesses and trade noting that Canada is the only G7 country on the 2023 United States Trade Representative Watchlist, (iv) meet directly with the Customs Immigration Union to ensure that the frontline officers participate in the process to reestablish increased searches, identification and counterfeit products processes; and (b) how much estimated value has been confiscated each year from this program and from how many seizures for the last ten years at all ports of entry to Canada?

Q-2922² — June 18, 2024 — — With regard to the federal target of achieving 100% Zero Emission Vehicle (ZEV) market share in Canada by 2035: (a) what is the government doing now, and what was done to date to address the lack of available public charging stations throughout the country to meet the demand for ZEVs; (b) what is the number of current public charging stations available through Canada, including locations, number, and types of chargers; (c) what is the projected number of public charging stations needed to meet demand by 2035; (d) did the government consider or have plans to increase the amount of the federal Incentives for Zero-Emission Vehicles Program (iZEV) from $5000; (e) did the government consider or have plans to match the United States’ federal incentive program to provide an equal and fair incentive for purchasing domestic vehicles; (f) did the government consider a plan for federal incentives for consumer purchases of used electric vehicles to help drive the sales and meet the environmental targets; (g) is the government tracking the import and export of new and used electric vehicles, and, if so, is it starting from the year 2022; and (h) is the government tracking the movement of electric vehicles purchased in one province the later moved to another province?

Q-2923² — June 18, 2024 — — With regard to the proposed deep geologic repository (DGR) plan by the Nuclear Waste Management Organization (NWMO) which could be located in South Bruce, Ontario: (a) should this site be selected, which falls within the Great Lakes basin, has the government (i) met with members of the United States Congress and United States Senate, or with our Canadian Ambassador to the United States, to hear the American concerns and opposition about storage of nuclear waste near, or within, the Great Lakes Basin, and, if so, who did they meet with, where were the meetings held and when, (ii) followed the progress of Amendment #947 to the to the FY 25 National Defense Authorization Act in U.S. Congress which calls for both Canada and the United States to not develop facilities to permanently store nuclear waste in the Great Lakes Basin and which has now moved to the United States Senate for further action and support, (iii) discussed with the NWMO alternatives to transporting and storing radioactive waste in the Great Lakes basin, (iv) considered alternatives to DGRs, such as recycling the radioactive waste, such as France, Japan, Germany and Belgium; (b) has the Prime Minister, the Minister of Export Promotion, International Trade and Economic Development or the Minister of Innovation, Science and Industry raised or responded to this issue to the President or other representative of the Biden Administration, and, if so, when and where did the meetings take place and with who?

Q-2924² — June 18, 2024 — — With regard to VIA HFR – Dedicated Project Office 2023-2024 Operating Budget: (a) for each individual paid under “Technical Office: specialized individuals hired under contractual agreements”, (i) what was the average payment, (ii) what was the highest amount of payment, (iii) how many unique individuals received payment; and (b) what are the details of all entities paid under “Technical Office: Engineering, accounting, procurement, legal, technical and communication services”, including the (i) date of the payment, (ii) date signed, (iii) value, (iv) detailed description of the service(s) provided, (v) start and end dates of work, (vi) details on how the contract was awarded (sole-sourced, competitive bid), (vii) titles of the officials who approved or signed off on the contract?

Q-2925² — June 18, 2024 — — With regard to all infrastructure projects that have received government funding since November 4, 2015, that require the use of steel: (a) what percentage of projects used only steel produced in Canada; (b) what percentage of projects partially used steel produced in Canada; and (c) what percentage of projects used steel produced outside of Canada?

Q-2926² — June 18, 2024 — — With regard to the federal carbon tax collected from the transportation sector, since April 1, 2019, broken down by year: (a) what were the amounts collected from Canadian Airports; (b) what were the amounts collected from (i) Canadian Airlines, (ii) non-Canadian Airlines; (c) what were the amounts collected from Canadian ports; (d) what were the amounts collected from (i) Canadian Maritime Transportation Companies, (ii) non-Canadian Maritime Transportation Companies; (e) what were the amounts collected from (i) Canadian trucking companies, (ii) non-Canadian trucking companies?

Q-2927² — June 18, 2024 — — With regard to the 21 privately-operated airport authorities in Canada: (a) what were the amount of rents collected from each airport authority since January 1, 2016, broken down by year; (b) what were the amounts of other fees or penalties collected from each airport authority since January 1, 2016, broken down by year, in total, and broken down by type of fee or penalty; and (c) since January 1, 2016, broken down by year, (i) how many projects at the 21 airports received funding by the federal government, (ii) what was the amount of funding received, broken down by project?

Q-2928² — June 18, 2024 — — With regard to carbon pricing on government administration, including the Carbon Tax and the Carbon Rebate, since January 1, 2019: (a) how much did the Government of Canada collect in each riding and province during each calendar year in carbon tax, broken down by (i) federal administration, (ii) provincial administration, (iii) municipal administration; (b) how much did the Government of Canada return in each riding and province during each calendar year through the Carbon Rebate, broken down by (i) federal administration, (ii) provincial administration, (iii) municipal administration; (c) of (a)(i) and (b)(i), what is the breakdown of the movement of funds from (i) central agencies, (ii) ministerial departments, (iii) separate agencies with direct ministerial oversight, (iv) independent agencies and offices, (v) independent review bodies, (vi) branches of the Canadian Armed Forces, (vii) the Senate of Canada, (viii) the House of Commons, (ix) federal courts, (x) special operating agencies, (xi) Crown corporations, (xii) Canadian Coast guard auxiliary, (xiii) federal infrastructure projects; (d) of (a)(ii) and (b)(ii), what is the breakdown of the movement of funds from (i) provincial agencies, (ii) ministerial departments, (iii) separate agencies with direct ministerial oversight, (iv) independent agencies and offices, (v) independent review bodies, (vi) provincial legislatures, (vii) provincial courts, (viii) special operating agencies, (ix) Crown corporations, (x) provincial courts, (xi) school boards and school divisions, (xii) health authorities, (xiii) public post-secondary institutions, (xiv) provincial infrastructure projects; and (e) of (a)(iii) and (b)(iii), what is the breakdown of the movement of funds from (i) municipal administration, (ii) museums and art galleries, (iii) curling rinks, (iv) hockey arenas, (v) pools, (vi) recreational centres, (vii) stadiums, (viii) community centres, (ix) municipal infrastructure projects, (x) visitor centres, (xi) homeless shelters, (xii) parks, (xiii) emergency response, (xiv) enforcement services?

Q-2929² — June 18, 2024 — — With regard to federally funded research for children’s illnesses: (a) how much federal funding was given out since 2015, broken down (i) year, (ii) province, (iii) illness, (iv) organization type; (b) which organizations received funding; (c) of (b), how much did each organization received, broken down by total amount (i) under $1000, (ii) $1,000 to $4,999, (iii) $5,000 to $9,999, (iv) $10 000 to $24,999, (v) $25,000 to $49,9999, (vi) $50,000 to $99,999, (vii) $100,000 to $249,999, (viii) $250,000 to $499,999, (ix) $500,000 to $999,999, (x) more than $1,000,000; (d) how many funding opportunities were available; (e) how many applications were received; (f) how many applications were accepted; (g) how much did Health Canada spend in-house; and (h) what reports were provided to the Government of Canada?

Q-2930² — June 18, 2024 — — With regard to training and professional development for Government of Canada employees, broken down by year since 2015: (a) what was the total cost; (b) what was the total cost of onboarding training, broken down by (i) basic training for new employees, (ii) health and safety training, (iii) mental health training, (iv) security training, (v) other; (c) what was total cost of skill-based training, broken down by (i) language training, (ii) technology training, (iii) financial management training, (iv) HR training, (v) other; (d) what was the total cost of professional development, broken down by length of employment (i) less than three months, (ii) three to five months, (iii) six to 12 months, (iv) one to two years, (v) two to five years, (vi) six to 10 years, (vii) 11 to 15 years, (viii) more than 15 years; (e) what the total cost of career transition training; (f) of employees who participation career transition training, how many continued to work for the Government of Canada for (i) less than one year, (ii) two to five years; (g) what was number of employees who spend more that 10% of their paid hours dedicated to organizing and administrating training and professional development for other Government of Canada employees; (h) what was the total cost of compensation for employees who spend more that 10% of their paid hours dedicated to organizing and administrating training and professional development for other Government of Canada employees; (i) what was the total cost of outside contracts broken down by training type; (j) what was the total number of paid work hours spent by Government of Canada employees to complete training and professional development; (k) what was total cost to complete training, broken down by (i) transportation, (ii) accommodations, (iii) per-diem, (iv) other; (l) what was the total amount given to post-secondary institutions; and (m) how many employees enrolled in at-least one course at an post-secondary institution?

Q-2931² — June 18, 2024 — — With regard to the safety of novel therapeutic products approved by Health Canada (HC) through Agile Licensing: (a) does HC determine the specifications required to be completed by the manufacturer to determine a therapeutic product’s safety for use by Canadians based primarily on its (i) therapeutic indication, (ii) pharmacological mechanism of action; (b) how does HC determine that a therapeutic product is safe; (c) what clinical and pre-clinical criteria are used by HC to make a safety assessment in regards to (i) vaccines, (ii) modified mRNA products, (iii) lipid nanotechnology, (iv) medications, (v) other biologics; (d) based on the pharmacological phase of the COVID-19 vaccines (i.e. from administration to spike protein expression), (i) are adverse events following immunizations adequately detected based on the Brighton Collaboration Criteria, (ii) what are the anticipated adverse events; (e) if the answer to (d)(i) is affirmative, how has this been confirmed; (f) what specific criteria were used to confirm the COVID-19 vaccines’ safety profile at their time of (i) approval, (ii) authorization; (g) based on the requirements in (b), (c) and (f), was that information adequate to categorically declare the safety of the COVID-19 vaccines for all cohorts at the time of their (i) approval, (ii) authorization; (h) does approval of a novel therapeutic product based on the Agile Licensing pathway require criteria that are equivalent to that required under C.08.001(2) of the Food and Drug Regulations; (i) if the answer to (g) or (h) is negative, who approved the messaging from government, public health officials, and other authorities that “COVID-19 vaccines do not get approval from HC unless they are safe” or that “all vaccines authorized in Canada are safe”; (j) how has safety of the COVID-19 vaccines been re-evaluated based on detected impurities, including (i) residual DNA, (ii) residual dsRNA, (iii) SV-40 enhancer sequence, (iv) endotoxins, (v) unknown peptides resulting from frameshifting; and (k) how has safety of the COVID-19 vaccine been evaluated based on remaining excessive intracellular N1-methylpseudouridine following degradation of the synthetic modified mRNA?

Notices of Motions for the Production of Papers

Business of Supply

Government Business

Private Members' Notices of Motions

Private Members' Business

C-379 — May 2, 2024 — Resuming consideration of the motion of , seconded by , — That Bill C-379, An Act to amend the Criminal Code (motor vehicle theft), be now read a second time and referred to the Standing Committee on Justice and Human Rights.

Pursuant to Standing Order 86(3), jointly seconded by:

— February 16, 2024

Debate — one hour remaining, pursuant to Standing Order 93(1).

Voting — at the expiry of the time provided for debate, pursuant to Standing Order 93(1).


² Response requested within 45 days

House Publications

Notice Paper

Introduction of Government Bills

Introduction of Private Members' Bills

Notices of Motions (Routine Proceedings)

Questions

Notices of Motions for the Production of Papers

Business of Supply

Government Business

Private Members' Notices of Motions

Private Members' Business